News

Jim Mellon-backed biotech to join Aim

Jim Mellon-backed biotech to join Aim
An experimental cancer drug discovered at Oxford University is the focus of a new UK biotech company to be listed in London this week led by two veterans of Bristol-Myers Squibb, the large US pharmaceuticals group.

An experimental cancer drug discovered at Oxford university is the focus of a new UK biotech company to be listed in London this week led by two veterans of Bristol-Myers Squibb, the large US pharmaceuticals group.

SalvaRX has been set up with backing from Jim Mellon, the Isle of Man-based investor, as an incubator for early-stage cancer drug developers.

Its first asset is iOx Therapeutics which is working on treatments using so-called natural killer T-cells to attack tumours.

Full Article available at the Financial Times.